Charlie Harper
BSc, MSc
Medical Statistician
Charlie is an Epidemiologist within the Wearables Group at the Big Data Institute and Oxford Population Health. His current research interests include the use of wearables data in risk prediction modelling and digital trial endpoints.
He joined the department in 2015 as a Medical Statistician and has contributed to numerous studies including large-scale randomised trials, meta-analyses, and observational studies in both cardiovascular and kidney disease.
Charlie obtained his DPhil in Population Health from Oxford Population Health, where he investigated whether routinely collected healthcare data can be used to reliably follow-up participants in large randomised trials.
He completed his undergraduate degree in Economics at the University of East Anglia and MSc in Economics at Bristol University.
Recent publications
-
Clinical trial results in context: comparison of baseline characteristics and outcomes of 38,510 RECOVERY trial participants versus a reference population of 346,271 people hospitalised with COVID-19 in England.
Journal article
Pessoa-Amorim G. et al, (2024), Trials, 25
-
Association of daily steps with incident non-alcoholic fatty liver disease: Evidence from the UK Biobank cohort
Preprint
Fulda ES. et al, (2024)
-
Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis.
Journal article
Cholesterol Treatment Trialists’ (CTT) Collaboration. Electronic address: ctt@ndph.ox.ac.uk None. and Cholesterol Treatment Trialists’ (CTT) Collaboration None., (2024), Lancet Diabetes Endocrinol, 12, 306 - 319
-
Getting our ducks in a row: The need for data utility comparisons of healthcare systems data for clinical trials.
Journal article
Sydes MR. et al, (2024), Contemp Clin Trials
-
Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial.
Journal article
RECOVERY Collaborative Group None., (2024), Lancet Child Adolesc Health, 8, 190 - 200